AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29952033 — intervention group
Group type: EXPERIMENTAL
Intervention: One-piece implant system (STM)
Number of subjects: 60
Study 27521607 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/Sulfamethoxazole (TMP-SMZ) 160 mg/800 mg, 1 tablet twice daily for 45 days, then 1 tablet every 2 days for 311 days
Number of subjects: 141
Study 27521607 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical tablet containing starch, no active ingredients), 1 tablet every 2 days for 311 days
Number of subjects: 141
Study 24504700 — intervention group
Group type: EXPERIMENTAL
Intervention: Danirixin 50 mg IR in fed state
Number of subjects: 20
Study 24504700 — intervention group
Group type: EXPERIMENTAL
Intervention: Danirixin 50 mg IR in fasted state
Number of subjects: 20
Study 24504700 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioenhanced Formulation 1 in fasted state
Number of subjects: 20
Study 24504700 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioenhanced Formulation 2 in fasted state
Number of subjects: 20
Study 24504700 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 20
Study 24504700 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioenhanced formulations
Number of subjects: 20
Study 21989324 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice alone
Number of subjects: 302
Study 21989324 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice plus FV vouchers (10-40 euros/month)
Number of subjects: 302
Study 21989324 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice plus FV vouchers
Number of subjects: 302
Study 19942479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab with FOLFOX6 (oxaliplatin, fluorouracil, and folinic acid)
Number of subjects: 114
Study 19942479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab with FOLFIRI (irinotecan, fluorouracil, and folinic acid)
Number of subjects: 114
Study 19942479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab with FOLFOX6
Number of subjects: 114
Study 19942479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab with FOLFIRI
Number of subjects: 114
Study 19942479 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS wild-type tumours
Number of subjects: 114
Study 19942479 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS-mutated tumours
Number of subjects: 114
Study 19942479 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (with cetuximab)
Number of subjects: 114
Study 18171954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injections of botulinum toxin A combined with hip abduction brace (6 hours/day)
Number of subjects: 90
Study 18171954 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 90
Study 15832334 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation of the dorsolateral prefrontal cortex by single pulses of varying field intensities.
Number of subjects: 3
Study 15832334 — intervention group
Group type: COMPARATOR
Intervention: General population controls with a high burden of complaints related to EMF exposure.
Number of subjects: 3
Study 15832334 — intervention group
Group type: COMPARATOR
Intervention: General population controls with a low burden of complaints related to EMF exposure.
Number of subjects: 3
Study 12695416 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering therapy
Number of subjects: 15
Study 12695416 — intervention group
Group type: COMPARATOR
Intervention: No blood pressure-lowering therapy
Number of subjects: 15
Study 12695416 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive subjects with type 2 diabetes
Number of subjects: 15
Study 10824628 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan with verapamil (120‐mg sustained‐release verapamil tablet twice daily for 7 days and one 12.5‐mg almotriptan tablet on day 7)
Number of subjects: 12
Study 10824628 — intervention group
Group type: COMPARATOR
Intervention: Almotriptan alone (one 12.5‐mg almotriptan tablet on day 7)
Number of subjects: 12
Study 10824628 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan with verapamil
Number of subjects: 12
Study 8870755 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol (1 g/kg)
Number of subjects: 44
Study 8870755 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 44
Study 1505149 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg diazepam
Number of subjects: 11
Study 1505149 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 11
Study 1505149 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 11
Study 1505149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1505149 — intervention group
Group type: COMPARATOR
Intervention: Control (2 mg diazepam)
Number of subjects: 11
Study 6356329 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicozamycin (500 mg, q.i.d. for 3 days)
Number of subjects: 250
Study 6356329 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulphamethoxazole (160 mg TMP‐SMX 800 mg, b.i.d. for 5 days)
Number of subjects: 250
Study 6356329 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (200 mg, b.i.d. for 5 days)
Number of subjects: 250
Study 6356329 — intervention group
Group type: COMPARATOR
Intervention: Placebo (first trial)
Number of subjects: 250
Study 6356329 — intervention group
Group type: COMPARATOR
Intervention: Placebo (second trial)
Number of subjects: 250
Study 30202072 — intervention group
Group type: EXPERIMENTAL
Intervention: Superonasal (SN) injection
Number of subjects: 1004
Study 30202072 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferonasal (IN) injection
Number of subjects: 1004
Study 30202072 — intervention group
Group type: EXPERIMENTAL
Intervention: Superotemporal (ST) injection
Number of subjects: 1004
Study 30202072 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferotemporal (IT) injection
Number of subjects: 1004
Study 28528560 — intervention group
Group type: EXPERIMENTAL
Intervention: Health scout intervention utilizing motivational interviewing strategies and a mobile phone-based counseling application.
Number of subjects: 771
Study 26505342 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon-α-2b (IFN-α-2b)
Number of subjects: 117
Study 26505342 — intervention group
Group type: COMPARATOR
Intervention: Control group (no high-dose IFN-α-2b)
Number of subjects: 117
Study 23868265 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive surgery
Number of subjects: 64
Study 23868265 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (Control)
Number of subjects: 64
Study 20924615 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide (300 mg/day)
Number of subjects: 80
Study 20924615 — intervention group
Group type: COMPARATOR
Intervention: NSAID (diclofenac sodium, 75 mg/day) and omeprazole (20 mg/day) with placebo
Number of subjects: 80
Study 20924615 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide co-therapy
Number of subjects: 80
Study 19177538 — intervention group
Group type: COMPARATOR
Intervention: Facilitated BMD testing
Number of subjects: 220
Study 19177538 — intervention group
Group type: COMPARATOR
Intervention: OP case manager intervention
Number of subjects: 220
Study 19177538 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 220
Study 17565828 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-reinforced posts and composite cores (Group A)
Number of subjects: 40
Study 17565828 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated titanium alloy posts and composite cores (Group B)
Number of subjects: 40
Study 17565828 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast nickel-chromium post-cores (Group C)
Number of subjects: 40
Study 17565828 — intervention group
Group type: COMPARATOR
Intervention: Control group (cast nickel-chromium post-cores and metal-ceramic crowns)
Number of subjects: 40
Study 15377321 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg phenazone
Number of subjects: 208
Study 15377321 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 208
Study 15868348 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient group living
Number of subjects: 314
Study 15868348 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home residents
Number of subjects: 314
Study 15868348 — intervention group
Group type: COMPARATOR
Intervention: Home care
Number of subjects: 314
Study 15868348 — intervention group
Group type: COMPARATOR
Intervention: Outpatient care or day care
Number of subjects: 314
Study 10511067 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 4 mg/70 kg
Number of subjects: 14
Study 10511067 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 8 mg/70 kg
Number of subjects: 14
Study 10511067 — intervention group
Group type: COMPARATOR
Intervention: Higher dosing regimens (48, 72, 96 hours)
Number of subjects: 14
Study 7489530 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine-GITS 30 mg
Number of subjects: 173
Study 7489530 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine-GITS 60 mg
Number of subjects: 173
Study 7489530 — intervention group
Group type: COMPARATOR
Intervention: nifedipine-PA
Number of subjects: 173
Study 7489530 — intervention group
Group type: COMPARATOR
Intervention: nifedipine-GITS
Number of subjects: 173
Study 1722967 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose iloprost (0.5 ng/kg/min)
Number of subjects: 55
Study 1722967 — intervention group
Group type: COMPARATOR
Intervention: Standard dose iloprost (2 ng/kg/min)
Number of subjects: 55
Study 1722967 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses
Number of subjects: 55
Study 6293717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 gm, perioperatively and up to 2 hours postoperatively)
Number of subjects: 133
Study 6293717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 gm, perioperatively and for 24 hours postoperatively)
Number of subjects: 133
Study 6293717 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (1 gm, perioperatively and for 24 hours postoperatively)
Number of subjects: 133
Study 31865326 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (1 strength, 10,000 TU/mL)
Number of subjects: 87
Study 31865326 — intervention group
Group type: COMPARATOR
Intervention: Group II (standard, 7 injections with 1,000 TU/mL and 10,000 TU/mL)
Number of subjects: 87
Study 30762267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuminum cyminum L. (CuEO) essential oil, 75 mg, thrice daily for 8 weeks
Number of subjects: 56
Study 30762267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuminum cyminum L. (CuEO) essential oil
Number of subjects: 56
Study 30762267 — intervention group
Group type: COMPARATOR
Intervention: Placebo soft gel
Number of subjects: 56
Study 28378318 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach (AA)
Number of subjects: 0
Study 28378318 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach (CA)
Number of subjects: 0
Study 28378318 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach (AA) in >5 cm tumors
Number of subjects: 0
Study 28378318 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach (CA) in >5 cm tumors
Number of subjects: 0
Study 27128727 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational therapy in addition to routine follow-up
Number of subjects: 59
Study 27128727 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up without psychoeducation
Number of subjects: 59
Study 24613632 — intervention group
Group type: EXPERIMENTAL
Intervention: WDYD intervention (n=456)
Number of subjects: 907
Study 24613632 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n=451: no intervention)
Number of subjects: 907
Study 24613632 — intervention group
Group type: EXPERIMENTAL
Intervention: WDYD intervention
Number of subjects: 907
Study 22622651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided PICC insertion
Number of subjects: 42
Study 22622651 — intervention group
Group type: COMPARATOR
Intervention: Control group (vein visualization and palpation)
Number of subjects: 42
Study 17882136 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg iron and 1 mg riboflavin weekly for 6 months
Number of subjects: 645
Study 17882136 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg zinc and 1 mg riboflavin weekly for 6 months
Number of subjects: 645
Study 17882136 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg iron, 20 mg zinc and 1 mg riboflavin weekly for 6 months
Number of subjects: 645
Study 17882136 — intervention group
Group type: COMPARATOR
Intervention: Riboflavin alone (control) weekly for 6 months
Number of subjects: 645
Study 17245230 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-nucleoside (ZDV/3TC/ABC)
Number of subjects: 0
Study 17245230 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-drug efavirenz (ZDV/3TC + EFV)
Number of subjects: 0
Study 17245230 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug efavirenz (ZDV/3TC/ABC + EFV)
Number of subjects: 0
Study 17245230 — intervention group
Group type: COMPARATOR
Intervention: ZDV/3TC/ABC
Number of subjects: 0
Study 17245230 — intervention group
Group type: EXPERIMENTAL
Intervention: All study participants
Number of subjects: 0
Study 15911866 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus docetaxel
Number of subjects: 186
Study 15911866 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 186
Study 11923756 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 microg subcutaneous)
Number of subjects: 340
Study 11923756 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg intravenous)
Number of subjects: 340
Study 11923756 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 340
Study 11923756 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Octreotide, Hydrocortisone, Placebo)
Number of subjects: 340
Study 9872337 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate/tretinoin gel
Number of subjects: 0
Study 9872337 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin HCl/tretinoin gel
Number of subjects: 0
Study 9872337 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin phosphate lotion (1% clindamycin; Dalacin T)
Number of subjects: 0
Study 9872337 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate/tretinoin gel in acne patients
Number of subjects: 0
Study 7613151 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen injection immunotherapy
Number of subjects: 0
Study 7613151 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids
Number of subjects: 0
Study 31494047 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest Computed Tomography (CT)
Number of subjects: 36
Study 31494047 — intervention group
Group type: COMPARATOR
Intervention: Chest Radiography (CR)
Number of subjects: 36
Study 31008759 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of autologous platelet-rich plasma and fibrin glue (PRP-FG) into the wound after wide excision of the sinus with primary closure
Number of subjects: 40
Study 31008759 — intervention group
Group type: COMPARATOR
Intervention: Wide excision of the sinus with primary closure (Control group)
Number of subjects: 40
Study 27056207 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 58
Study 27056207 — intervention group
Group type: COMPARATOR
Intervention: Control group (general anaesthesia alone)
Number of subjects: 58
Study 26112050 — intervention group
Group type: COMPARATOR
Intervention: Usual follow-up visits and aftercare provided in secondary care
Number of subjects: 300
Study 26112050 — intervention group
Group type: COMPARATOR
Intervention: Usual follow-up visits and aftercare provided in secondary care with additional use of Oncokompas(2.0)
Number of subjects: 300
Study 26112050 — intervention group
Group type: COMPARATOR
Intervention: Follow-up and aftercare in primary care
Number of subjects: 300
Study 26112050 — intervention group
Group type: COMPARATOR
Intervention: Follow-up and aftercare in primary care with additional use of Oncokompas(2.0)
Number of subjects: 300
Study 23480640 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily darunavir/ritonavir (DRV/r) 800/100 mg
Number of subjects: 590
Study 23480640 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily darunavir/ritonavir (DRV/r) 600/100 mg
Number of subjects: 590
Study 20627942 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow infusion of antithrombin concentrate (100 IU/min) before full-dose heparinisation
Number of subjects: 40
Study 20627942 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast infusion of antithrombin concentrate (250 IU/min)
Number of subjects: 40
Study 20627942 — intervention group
Group type: COMPARATOR
Intervention: Both groups (slow and fast infusion)
Number of subjects: 40
Study 17091331 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose adjuvant chemotherapy (mitomycin and tegafur-uracil)
Number of subjects: 1410
Study 17091331 — intervention group
Group type: COMPARATOR
Intervention: Low-dose adjuvant chemotherapy (mitomycin and tegafur-uracil)
Number of subjects: 1410
Study 15602113 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg paroxetine
Number of subjects: 29
Study 15602113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 12145379 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management of incontinence
Number of subjects: 74
Study 12145379 — intervention group
Group type: EXPERIMENTAL
Intervention: Attribution of incontinence to aging
Number of subjects: 74
Study 12145379 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception that incontinence restricted activities
Number of subjects: 74
Study 12080675 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianlong xifeng granule (TXG)
Number of subjects: 412
Study 12080675 — intervention group
Group type: COMPARATOR
Intervention: Xixian tongshuan pill (XTP)
Number of subjects: 412
Study 8614309 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmvitee (40 mg alpha-tocopherol, 48 mg alpha-tocotrienol, 112 mg gamma-tocotrienol, and 60 mg delta-tocotrienol/day for four weeks)
Number of subjects: 52
Study 8614309 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg gamma-tocotrienol/day for four weeks
Number of subjects: 52
Study 8614309 — intervention group
Group type: COMPARATOR
Intervention: Dietary regimen alone
Number of subjects: 52
Study 8614309 — intervention group
Group type: COMPARATOR
Intervention: Dietary assessments
Number of subjects: 52
Study 8614309 — intervention group
Group type: COMPARATOR
Intervention: alpha-Tocopherol
Number of subjects: 52
Study 8614309 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocotrienol preparations
Number of subjects: 52
Study 8614309 — intervention group
Group type: COMPARATOR
Intervention: Neither preparation
Number of subjects: 52
Study 2076798 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal glucagon (1 mg)
Number of subjects: 18
Study 2076798 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous glucagon (1 mg)
Number of subjects: 18
Study 2076798 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycocholic acid (1 mg)
Number of subjects: 18
Study 7039058 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin (1 mg/kg/iv q8h)
Number of subjects: 36
Study 7039058 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin (1 mg/kg/iv q8h)
Number of subjects: 36
Study 30328105 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (selective serotonin reuptake inhibitor)
Number of subjects: 33
Study 28655183 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered therapist-guided cognitive behavior therapy for insomnia
Number of subjects: 43
Study 28655183 — intervention group
Group type: COMPARATOR
Intervention: Internet-delivered therapist-guided cognitive behavior therapy for depression
Number of subjects: 43
Study 24332687 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthesia with cocaine 4% pledgets
Number of subjects: 92
Study 24332687 — intervention group
Group type: COMPARATOR
Intervention: Topical anaesthesia with lidocaine 2% plus 1/100.000 adrenaline pledgets
Number of subjects: 92
Study 22849337 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 6.25‐12.5 mg daily
Number of subjects: 121
Study 22849337 — intervention group
Group type: COMPARATOR
Intervention: Nadolol 40‐80 mg plus isosorbide‐5‐mononitrate 20 mg daily
Number of subjects: 121
Study 19726349 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral plus enteral nutrition (PN+EN)
Number of subjects: 20
Study 19726349 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 20
Study 17682411 — intervention group
Group type: EXPERIMENTAL
Intervention: RPCP (Respecting Patient Choices Program)
Number of subjects: 0
Study 17682411 — intervention group
Group type: COMPARATOR
Intervention: Pre-intervention and control groups
Number of subjects: 0
Study 16301340 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (25 mg QD increasing to 200 mg QD)
Number of subjects: 56
Study 16301340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 12385358 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue coblation
Number of subjects: 10
Study 12385358 — intervention group
Group type: COMPARATOR
Intervention: Bipolar dissection
Number of subjects: 10
Study 9456273 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 120 mg sustained-release once daily
Number of subjects: 16
Study 9456273 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine 8 mg sustained-release 3 times daily
Number of subjects: 16
Study 9456273 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 16
Study 9456273 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine
Number of subjects: 16
Study 7887879 — intervention group
Group type: EXPERIMENTAL
Intervention: in vivo exposure plus disconfirmation of misappraisals of bodily sensations
Number of subjects: 70
Study 7887879 — intervention group
Group type: EXPERIMENTAL
Intervention: in vivo exposure plus relaxation
Number of subjects: 70
Study 2146996 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusions of third-party donor leucocytes
Number of subjects: 0
Study 2146996 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking effect index (BEI)
Number of subjects: 0